Sonoma Pharmaceuticals Inc (SNOA) - Total Assets
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) holds total assets worth $13.62 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Sonoma Pharmaceuticals Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Sonoma Pharmaceuticals Inc - Total Assets Trend (2002–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore SNOA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Sonoma Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Sonoma Pharmaceuticals Inc's total assets of $13.62 Million consist of 92.4% current assets and 7.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.3% |
| Accounts Receivable | $3.76 Million | 27.5% |
| Inventory | $2.92 Million | 21.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sonoma Pharmaceuticals Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sonoma Pharmaceuticals Inc's current assets represent 92.4% of total assets in 2025, an increase from 45.3% in 2002.
- Cash Position: Cash and equivalents constituted 39.3% of total assets in 2025, down from 45.3% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 27.5% of total assets.
Sonoma Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Sonoma Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Huadong Medicine Co Ltd
SHE:000963
|
China | CN¥39.93 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Celltrion Pharm Inc
KQ:068760
|
Korea | ₩745.80 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
Sonoma Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 3.34 | 3.18 |
| Quick Ratio | 2.00 | 2.49 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.93 Million | $8.68 Million | $8.90 Million |
Sonoma Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Sonoma Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.36 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | $13.69 Million |
| Market Capitalization | $3.99 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sonoma Pharmaceuticals Inc's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sonoma Pharmaceuticals Inc's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sonoma Pharmaceuticals Inc (2002–2025)
The table below shows the annual total assets of Sonoma Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $13.69 Million | -7.10% |
| 2024-03-31 | $14.74 Million | -9.19% |
| 2023-03-31 | $16.23 Million | -13.87% |
| 2022-03-31 | $18.84 Million | +25.74% |
| 2021-03-31 | $14.99 Million | +2.93% |
| 2020-03-31 | $14.56 Million | +0.78% |
| 2019-03-31 | $14.45 Million | -24.77% |
| 2018-03-31 | $19.21 Million | -24.56% |
| 2017-03-31 | $25.46 Million | +84.45% |
| 2016-03-31 | $13.80 Million | -8.27% |
| 2015-03-31 | $15.05 Million | -27.62% |
| 2014-03-31 | $20.79 Million | +65.47% |
| 2013-03-31 | $12.56 Million | +60.31% |
| 2012-03-31 | $7.84 Million | -9.53% |
| 2011-03-31 | $8.66 Million | -15.21% |
| 2010-03-31 | $10.22 Million | +87.59% |
| 2009-03-31 | $5.45 Million | -76.93% |
| 2008-03-31 | $23.61 Million | -12.39% |
| 2007-03-31 | $26.95 Million | +112.39% |
| 2006-03-31 | $12.69 Million | +82.84% |
| 2005-03-31 | $6.94 Million | +622.16% |
| 2003-03-31 | $961.00K | -43.03% |
| 2002-03-31 | $1.69 Million | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more